From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review

被引：7

作者：

Comont, Thibault ^{[1
,2
,3
]}

Treiner, Emmanuel ^{[3
,4
,5
]}

Vergez, Francois ^{[2
,3
,6
]}

机构：

[1] Toulouse Univ Hosp, CHU Toulouse, Dept Internal Med, IUCT Oncopole, F-31300 Toulouse, France

[2] CNRS, Canc Res Ctr Toulouse, UMR 1037, INSERM,ERL5294, F-31100 Toulouse, France

[3] Univ Toulouse III Paul Sabatier, Sch Med, F-31062 Toulouse, France

[4] Toulouse Univ Hosp, Lab Immunol, CHU Toulouse, F-31300 Toulouse, France

[5] Infinity, Inserm UMR1291, F-31000 Toulouse, France

[6] Toulouse Univ Hosp, CHU Toulouse, Lab Hematol, IUCT Oncopole, F-31300 Toulouse, France

来源：

DIAGNOSTICS | 2021年 / 11卷 / 11期

关键词：

myelodysplastic syndromes; immune; inflammation; T-cell; ACUTE MYELOID-LEUKEMIA; WT1 PEPTIDE VACCINATION; REGULATORY T-CELLS; HEMATOPOIETIC PROGENITOR CELLS; TRANSFUSION-DEPENDENT PATIENTS; PROGNOSTIC SCORING SYSTEM; NECROSIS-FACTOR-ALPHA; CLONAL HEMATOPOIESIS; BONE-MARROW; DENDRITIC CELLS;

D O I：

10.3390/diagnostics11111982

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The pathophysiology of myelodysplastic syndromes (MDSs) is complex and often includes immune dysregulation of both the innate and adaptive immune systems. Whereas clonal selection mainly involves smoldering inflammation, a cellular immunity dysfunction leads to increased apoptosis and blast proliferation. Addressing immune dysregulations in MDS is a recent concept that has allowed the identification of new therapeutic targets. Several approaches targeting the different actors of the immune system have therefore been developed. However, the results are very heterogeneous, indicating the need to improve our understanding of the disease and interactions between chronic inflammation, adaptive dysfunction, and somatic mutations. This review highlights current knowledge of the role of immune dysregulation in MDS pathophysiology and the field of new drugs.

引用

页数：19

共 183 条

[1] Interpreting new molecular genetics in myelodysplastic syndromes [J].

Abdel-Wahab, Omar ;

Figueroa, Maria E. .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, :56-64

[2] An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis [J].

Abegunde, Samuel O. ;

Buckstein, Rena ;

Wells, Richard A. ;

Rauh, Michael J. .

EXPERIMENTAL HEMATOLOGY, 2018, 59 :60-65

[3] Natural Killer Cell (NK) Subsets and NK-Like T-Cell Populations in Acute Myeloid Leukemias and Myelodysplastic Syndromes [J].

Aggarwal, N. ;

Swerdlow, S. H. ;

TenEyck, S. P. ;

Boyiadzis, M. ;

Felgar, R. E. .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (04) :349-357

[4] Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia [J].

Anguille, Sebastien ;

Van de Velde, Ann L. ;

Smits, Evelien L. ;

Van Tendeloo, Viggo F. ;

Juliusson, Gunnar ;

Cools, Nathalie ;

Nijs, Griet ;

Stein, Barbara ;

Lion, Eva ;

Van Driessche, Ann ;

Vandenbosch, Irma ;

Verlinden, Anke ;

Gadisseur, Alain P. ;

Schroyens, Wilfried A. ;

Muylle, Ludo ;

Vermeulen, Katrien ;

Maes, Marie-Berthe ;

Deiteren, Kathleen ;

Malfait, Ronald ;

Gostick, Emma ;

Lammens, Martin ;

Couttenye, Marie M. ;

Jorens, Philippe ;

Goossens, Herman ;

Price, David A. ;

Ladell, Kristin ;

Oka, Yoshihiro ;

Fujiki, Fumihiro ;

Oji, Yusuke ;

Sugiyama, Haruo ;

Berneman, Zwi N. .

BLOOD, 2017, 130 (15) :1713-1721

[5]

[Anonymous], 2016, BLOOD, DOI [DOI 10.1182/BLOOD.V128.22.4335.4335, 10.1182/blood.V128.22.4335.4335, DOI 10.1182/blood.V128.22.4335.4335]

[6] Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes [J].

Asayama, Toshio ;

Tamura, Hideto ;

Ishibashi, Mariko ;

Kuribayashi-Hamada, Yasuko ;

Onodera-Kondo, Asaka ;

Okuyama, Namiko ;

Yamada, Akiko ;

Shimizu, Masumi ;

Moriya, Keiichi ;

Takahashi, Hidemi ;

Inokuchi, Koiti .

ONCOTARGET, 2017, 8 (51) :88904-88917

[7] Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia [J].

Atanackovic, Djordje ;

Luetkens, Tim ;

Kloth, Benjamin ;

Fuchs, Gregor ;

Cao, Yanran ;

Hildebrandt, York ;

Meyer, Sabrina ;

Bartels, Katrin ;

Reinhard, Henrike ;

Lajmi, Nesrine ;

Hegewisch-Becker, Susanna ;

Schilling, Georgia ;

Platzbecker, Uwe ;

Kobbe, Guido ;

Schroeder, Thomas ;

Bokemeyer, Carsten ;

Kroeger, Nicolaus .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (11) :918-922

[8] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [J].

Attar, Eyal C. ;

Amrein, Philip C. ;

Fraser, James W. ;

Fathi, Amir T. ;

McAfee, Steven ;

Wadleigh, Martha ;

DeAngelo, Daniel J. ;

Steensma, David P. ;

Stone, Richard M. ;

Foster, Julia ;

Neuberg, Donna ;

Ballen, Karen K. .

LEUKEMIA RESEARCH, 2013, 37 (09) :1016-1020

[9] A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS) [J].

Bachier, Carlos ;

Borthakur, Gautam ;

Hosing, Chitra ;

Blum, William ;

Rotta, Marcello ;

Ojeras, Paulius ;

Barnett, Brian ;

Rajangam, Kanya ;

Majhail, Navneet S. ;

Nikiforow, Sarah .

BLOOD, 2020, 136

[10]

Ball M., 2020, HEMATOPOIETIC STEM C, V2020, P230433, DOI [DOI 10.1101/2020.08.01.230433, 10.1101/2020.08.01.230433]

← 1 2 3 4 5 6 7 8 9 10 →